Press Releases Clene Inc.

Equities

CLNN

US1856341029

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-26 EDT			5-day change	1st Jan Change
0.3511 ^USD	-2.47%		-7.63%	+18.37%

06-21	Clene Says Lead Drug Candidate Shows Potential to Treat Rett Syndrome	MT
06-21	Clene Inc. and Clene Nanomedicine Inc. Present Preliminary Data for CNM-Au8 as Potential Treatment for Rett Syndrome	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference	06-24	AQ
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome	06-21	AQ
Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting	06-18	AQ
Clene to Present at the Emerging Growth Conference	06-05	AQ
Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)	05-28	AQ
Clene to Present at Upcoming May Conferences	05-14	AQ
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights	05-08	AQ
IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington	05-01	AQ
Clene : 2023 Annual Report to Stockholders	04-17	PU
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting	04-16	AQ
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington	03-19	AQ
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®	03-15	AQ
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights	03-13	AQ
Clene to Present at the 36th Annual ROTH Conference	03-07	AQ
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024	02-29	AQ
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs	02-22	AQ
Clene Inc. announces positive results from CNM-Au8 results from MS trial	02-05	AQ
Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension	01-08	AQ
Clene Provides Update on ALS Clinical Development Meeting With FDA	12-21	AQ
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension	12-21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Clene Inc.

Equities

CLNN

US1856341029

Press Releases

Filters